Executives And Founders Of Uber, Facebook And Apple Are Bullish On This Wellness App — You Can Coinvest At $1.15 Per Share

Últimas noticias sobre Aura Biosciences (NASDAQ:AURA) Bolsa

AURA BIOSCIENCES INC

Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Movers

Trading Ideas

ARKR

AURA

BLRX

CHEK

CMCT

COEP

IDAI

LINC

MGOL

NINE

RSVR

Conoce las acciones que lideran el premercado tras movimientos clave: Check-Cap sube un 52,2% gracias a nueva patente.

Las acciones de Check-Cap suben un 52%; 20 acciones que se están moviendo antes de la apertura del mercado

Aura Biosciences Inc

Aura Energy Ltd

Aura Fat Projects Acquisition Corp Ordinary Shares - Class A

Aura Fat Projects Acquisition Corp

Aura Fat Projects Acquisition Corp Units (1 Ord Class A & 1 War)

Aura Fat Projects Acquisition Corp Warrants(31/03/2027)

Aura Minerals Inc

Aura Systems Inc

AuraSource Inc

AURANIA RESOURCES ORD by Aurania Resources, Ltd.

Aurania Resources Ltd

Aurania Resources Ltd Warrants (21/10/2026)

CME Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CME#NYSE">CME</a>) short percent of float has fallen 12.66% since its last report. The company recently reported that it has 4.96 million shares sold short, which is 1.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CME Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746720029_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CME Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CME Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CME Group's peer group average for short interest as a percentage of float is 3.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into CME Group's Recent Short Interest

Monster Beverage's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NYSE">MNST</a>) short percent of float has risen 10.36% since its last report. The company recently reported that it has 19.03 million shares sold short, which is 2.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Monster Beverage Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746720024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monster Beverage has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Monster Beverage's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Monster Beverage's peer group average for short interest as a percentage of float is 7.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MNST

What Does the Market Think About Monster Beverage?

C.H. Robinson Worldwide's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NYSE">CHRW</a>) short percent of float has risen 4.97% since its last report. The company recently reported that it has 5.23 million shares sold short, which is 5.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>C.H. Robinson Worldwide Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746720019_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for C.H. Robinson Worldwide has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing C.H. Robinson Worldwide's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, C.H. Robinson Worldwide's peer group average for short interest as a percentage of float is 3.16%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CHRW

How Do Investors Really Feel About C.H. Robinson Worldwide?

RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) has outperformed the market over the past 10 years by 3.32% on an annualized basis producing an average annual return of 13.81%. Currently, RB Global has a market capitalization of $19.15 billion. 
Buying $100 In RBA: If an investor had bought $100 of RBA stock 10 years ago, it would be worth $367.57 today based on a price of $103.47 for RBA at the time of writing.
<h3>RB Global's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746720014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Here's How Much $100 Invested In RB Global 10 Years Ago Would Be Worth Today

Keybanc analyst Jason Celino maintains Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) with a Overweight and raises the price target from $245 to $270.

Price Target

Analyst Ratings

PAYC

Keybanc Maintains Overweight on Paycom Software, Raises Price Target to $270

CIBC analyst Anita Soni maintains Iamgold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) with a Outperformer and raises the price target from $8.4 to $9.2.

CIBC Maintains Outperformer on Iamgold, Raises Price Target to $9.2

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) with a Outperform and raises the price target from $42 to $44.

EVTC

Keefe, Bruyette & Woods Maintains Outperform on Evertec, Raises Price Target to $44

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low</a>

Biotech

General

VSTM

'FDA Grants Accelerated Approval To The Combination Of Avutometinib And Defactinib For KRAS-Mutated Recurrent Low-grade Serous Ovarian Cancer'

Macro Economic Events

Market Summary

Economics

$BTC

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Benzinga Market Summary: S&P Rises As Trump Unveils UK Trade Framework, Bitcoin Surpasses $100K, Chip Stocks Higher Following Wednesday Report Suggesting Trump Will Rescind Global Chip Curbs

<a href="https://www.youtube.com/watch?v=WElDJC0Q_kQ" title="https://www.youtube.com/watch?v=WElDJC0Q_kQ">https://www.youtube.com/watch?v=WElDJC0Q_kQ</a>

Global

JBLU

ULCC

President Trump Says Now In Market To Buy Brand New Air Traffic Control System; Going Out To Bid Very Soon; ATC System Would Cover Entire World

Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Wall Street&#8217;s AI poster child and heart of the generative tech revolution, may have just experienced a voltage dip. The company&#8217;s largest growth driver, its <a href="https://www.benzinga.com/topic/nvidia">data center revenue</a>, is reportedly heading for a $9.8 billion-sized pothole should capital spending grind to a halt and Chinese demand continue to flatline, according to a new note from Piper Sandler.
Analyst Harsh Kumar cautioned that, worst case, around 6.45% of Nvidia&#8217;s data center revenue might be in jeopardy, exposed to capex cuts across data center end markets. If that materializes, he expects the share price to drop to $76.25, assuming a 25x multiple. That&#8217;s a far cry from the company&#8217;s reaffirmed $150 price target.
So, what&#8217;s an ETF investor to do when their artificially intelligent knight starts showing signs of rust? Here&#8217;s a glance at the <a href="https://www.benzinga.com/etfs">funds that might mitigate the pain</a>, or grab the opportunity.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44854262/chipwrecked-nvidias-export-ban-triggers-etf-meltdown-and-one-big-winner">Chipwrecked: Nvidia&#8217;s Export Ban Triggers ETF Meltdown (And One Big Winner)</a>
<ol>
<li>Nvidia Sneezes, They Catch A Cold</li>
</ol>
VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) – With more than 20% of its positions in NVDA, SMH is essentially a fan club. Wonderful during an AI bubble; dangerous when storms brew.
iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) – Likewise Nvidia-heavy at about 8–10% exposure, it&#8217;s a diversified play but still has significant downside risk if the GPU king falls.
Direxion Daily NVDA Bull 1.5X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>) – For those who prefer their risk leveraged and their stomachs iron-clad.
The bottom line is that these are high-octane plays—gorgeous on the way up, but can&#8217;t wait for a seatbelt on the way down.
<ol start="2">
<li>The Gentle Gliders</li>
</ol>
ROBO Global Robotics and Automation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROBO#NYSE">ROBO</a>) – Holds Nvidia, sure, but also a global buffet of robotics, automation, and industrial AI plays.
Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>) – Nvidia&#8217;s in there, but BOTZ offers more geographic diversification.
WisdomTree Artificial Intelligence and Innovation Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WTAI#BATS">WTAI</a>) – A thematic newcomer that bets on AI's long-term arc without going all-in on Nvidia.
<ol start="3">
<li>Safety First: Dividend &amp; Low-Volatility Tech Funds</li>
</ol>
First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>) – Taps income-tech with light exposure to Nvidia.
Invesco S&amp;P 500 Low Volatility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLV#NYSE">SPLV</a>) – Not tech-narrow, but defensive sanctuary should markets turn down.
Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – Still owns Nvidia, but watered down by a who&#8217;s-who of mega-cap tech; more of a tech index security blanket.
<ol start="4">
<li>The Contrarians: Betting on a Burnout</li>
</ol>
Direxion Daily Semiconductor Bear 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXS#NYSE">SOXS</a>) – Triple-leveraged short exposure to semis. Not for the faint of heart or long-term holders.
AXS Short Innovation Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SARK#NASDAQ">SARK</a>) – Playing against the ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>), which typically reflects sentiment across names such as Nvidia, Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), etc.
Caveat emptor: These aren&#8217;t hedges; they&#8217;re tactical nukes. It&#8217;s wise to assess your risk appetite before investing.
Also Read: <a href="https://www.benzinga.com/tech/25/05/45235394/nvidia-broadcom-lead-fund-manager-buys-even-as-semiconductor-sector-cools-analysts">Nvidia, Broadcom Lead Fund Manager Buys Even As Semiconductor Sector Cools: Analysts</a>
The Bigger Picture
Piper Sandler issued a cautionary note, but they remain bullish on Nvidia in the long run, reiterating its Overweight rating. The firm is still the unchallenged leader in AI infrastructure, with increasing sales of its Blackwell AI supercomputers and a strong lead in GPU-based AI acceleration.
However, future Q1 earnings and trade headwinds, particularly new U.S. export controls on AI chips, may test investors&#8217; conviction.
Nvidia will report Q1 in late May, with the Street looking for EPS of $0.89 (a 45% YoY increase) and revenue of $43 billion (a 65% gain), according to Forbes. If these figures hold or even beat to the upside, current pessimism could prove short-lived.
Final Byte
For ETF investors, the Nvidia wobble is not a cause for alarm. It&#8217;s a reminder to examine exposure, diversify carefully and perhaps have a few hedges up one&#8217;s sleeve. As with everything AI, the future is rosy but perhaps best seen through a slightly risk-adjusted pair of glasses.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45235676/exclusive-expert-explains-how-this-gold-etf-lets-you-physically-hold-your-wealth-and-why-investors-are-quietly-rushing-in">Exclusive: Expert Explains How This Gold ETF Lets You Physically Hold Your Wealth And Why Investors Are Quietly Rushing In</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

ARKK

BOTZ

NVDA

NVDU

ROBO

SARK

Direxion Daily Semiconductor Bear 3X Shares

SOXS

PowerShares S&P 500 Low Volatility Portfolio

SPLV

TDIV

TSLA

WisdomTree Trust WisdomTree Artificial Intelligence and Innovation Fund

WTAI

Alarm Bells For Nvidia As $9.8 Billion Blow Threatens A Crash: ETFs With Most Risk Or Opportunity

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/05/2025-05-08_08h36_31.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">The Devil Is In The Details</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-chip-restrictions-uk-trade-deal-nvda-mc-05082025">click here</a> for a chart of NVIDIA Corp (NVDA).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA stock is being used to illustrate the point.</li>
<li>The chart shows that NVDA stock moved above the top band of zone 3.&nbsp; Zone 3 was previously a resistance zone.&nbsp; Now, it has become a support zone.</li>
<li>The trigger behind the move in NVDA stock along with other semiconductor stocks is President Trump's plan to rescind chip export restrictions from the Biden era.&nbsp; These restrictions were designed to limit export of advanced chips to prevent China from catching up with the U.S.</li>
<li>In our analysis, buying is coming into semiconductors mostly from the momo crowd as the momo crowd rejoices in the removal of chip restrictions.  As usual, the momo crowd is not doing any analysis.</li>
<li>In our analysis, President Trump is not going to go any easier on the export of advanced chips to China than Biden.  President Trump is simply overhauling Biden era restrictions to make them simpler and more effective.  There is a high probability that new restrictions may turn out to be harsher than the old restrictions.  </li>
<li>As the momo crowd aggressively buys semiconductors, the momo crowd is also ignoring disappointing revenue projection from Arm Holdings PLC &#8211; ADR (ARM).  This information from Arm is important because Arm designs are in over 90% of smartphones.  ARM stock is falling about 7% as of this writing in the premarket.</li>
<li>Adding to the aggressive buying in the stock market this morning is a trade deal with the U.K.&nbsp; President Trump will announce the details of the trade deal at 10am ET.</li>
<li>In our analysis, prudent investors need to keep in mind the following key points:
<ul>
<li>The trade deal with the U.K. was expected to be the easiest.&nbsp;&nbsp;</li>
<li>A trade deal with the E.U. will not be as easy.&nbsp; The reason is trade between the U.K. and the U.S. has been mostly balanced, even before any trade deal.&nbsp;&nbsp;</li>
<li>President Trump is promising the U.K. deal will be full and comprehensive, but there is speculation that the U.K. trade deal may turn out to be somewhat limited.&nbsp;&nbsp;</li>
</ul>
</li>
<li>The most important trade deal will be with China, and it will be difficult.&nbsp; As an indication of what is to come, China's President Xi and Russia's President Putin met and are promising to fight what they are calling international bullying by the U.S.</li>
<li>Pharmaceutical stocks, such as Pfizer Inc (PFE), Merck &amp; Co Inc (MRK), Eli Lilly And Co (LLY), Novo Novo Nordisk A/S (NVO), Bristol-Myers Squibb Co (BMY), and Gilead Sciences Inc (GILD), and Moderna Inc (MRNA), may come under pressure as President Trump plans to significantly cut drug costs.</li>
<li>Initial jobless claims came at 228K vs. 238K consensus.&nbsp; This indicates that for the time being, the jobs picture remains strong.</li>
</ul>
<h4 class="wp-block-heading">India And Pakistan</h4>
As India and Pakistan try to de-escalate, they are also attacking each other with drones.&nbsp; Stocks in India fell by 0.4% but by 7% in Pakistan.&nbsp; Prudent investors need to keep an eye on the situation.
<h4 class="wp-block-heading">Bank Of England</h4>
The Bank of England (BOE) cut interest rates to 4.25%.&nbsp; This was inline with expectations.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Nvidia (NVDA), Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), and Tesla Inc (TSLA).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
There is jubilation as Bitcoin approaches $100K.  There is aggressive buying in bitcoin related stocks such as MicroStrategy Inc (MSTR), Coinbase Global Inc (COIN), Riot Platforms Inc (RIOT), and MARA Holdings Inc (MARA).
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Long Ideas

Broad U.S. Equity ETFs

Opinion

Buying In Nvidia On Chip Restriction Removal And UK Trade Deal, But Devil Is In The Details

President Trump Says Will Talk Soon With Heads Of Airlines

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>), Asset Entities, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>), Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) are the top five trending tickers on Stocktwits <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45274508/bitcoin-taps-98000-ethereum-dogecoin-steady-as-fed-chair-jerome-powell-raises-trump-tariff-induced-concerns-analyst-says-eth-holding-above-crucial-level-and-begins-its">Thursday.&nbsp;</a>
Here's a look at what is grabbing retail investors' attention.&nbsp;
QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record <a href="https://www.benzinga.com/pressreleases/25/05/b45280859/d-wave-reports-first-quarter-2025-results">quarterly revenue</a> before the opening bell. While $15 million may not sound impressive, it is a 509% increase from the prior year's quarter and retail investors are piling in.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a>
ASST: Asset Entities stock is volatile for the second day on Thursday following Wednesday's announcement that it <a href="https://www.benzinga.com/news/contracts/25/05/45260992/asset-entities-stock-rockets-higher-on-merger-deal-to-form-bitcoin-treasury-company">will merge</a> with Strive Asset Management to be the first publicly traded asset management Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury company. Trading has been halted multiple times for volatility and the stock is up over 100% at the time of publication.&nbsp;
GOOG: Alphabet suffered its worst <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45288753/google-at-staggering-42-discount-to-sp-500-after-150-billion-value-dive">trading day</a> since 2023, shedding nearly $150 billion in market cap, on Wednesday after Apple revealed it has been talking to ChatGPT and Perplexity about potential search partnerships. The stock is attempting to recover some losses Thursday, but Google's future search dominance remains in question.&nbsp;&nbsp;
NVAX: Retail traders are celebrating Novavax's massive<a href="https://www.benzinga.com/pressreleases/25/05/n45282885/novavax-reports-first-quarter-2025-financial-results-and-operational-highlights"> first-quarter earnings</a> beat that was released before Thursday's opening bell. The company reported earnings of $2.93 per share which beat the Street estimate of 71 cents by a whopping 312%. Novavax also reported nearly double the consensus revenue estimate and issued guidance well-above analysts' estimates.&nbsp;
CVNA: Carvana shares are driving higher on its better-than-expected Q1 earnings, as well as a slew of analysts' price target raises. The company reported<a href="https://www.benzinga.com/news/earnings/25/05/45268560/carvana-q1-earnings-revenue-eps-beat-estimates-as-vehicles-sales-jump-46-company-remains-on-track-for-significant-growth-in-fy25"> first-quarter earnings</a> of $1.51 per share, smashing analyst estimates of 60 cents per share.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45239803/sarepta-therapeutics-stock-plummets-after-q1-results-heres-why?utm_source=articleShare">Sarepta Therapeutics Stock Plummets After Q1 Results: Here&#8217;s Why </a></li>
</ul>
Image: Shutterstock

Earnings

Markets

ASST

CVNA

GOOG

GOOGL

NVAX

QBTS

Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana?

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid President Trump's US-UK trade framework.

Primo Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>) shares are <a href="https://www.benzinga.com/movers">trading lower on Thursday </a>after the first-quarter earnings. 
The company <a href="https://www.benzinga.com/pressreleases/25/05/n45279861/primo-brands-reports-first-quarter-2025-results">reported first-quarter</a> revenue growth of 42.1% year-on-year to $1.61 billion, missing the analyst consensus estimate of $1.62 billion.
Adjusted EPS of 29 cents <a href="https://www.benzinga.com/earnings">beat the consensus</a> estimate of 23 cents.
Gross margin was 32.3% primarily driven by gross profit attributable to&nbsp;Primo Water&nbsp;due to the merger transaction, as well as lower maintenance costs.
Also Read: <a href="https://www.benzinga.com/news/25/05/45285725/why-budweiser-parent-anheuser-busch-inbevs-stock-is-rising-today">Why Budweiser Parent Anheuser-Busch InBev&#8217;s Stock Is Rising Today?</a>
Selling, general and administrative expenses increased 49.9% to $327.8 million.
Primo Brands reported a 22.7% increase in operating income to $153.2 million with an operating margin of 9.4%.
Adjusted EBITDA for the quarter improved 56.9% to $341.5 million and the margin expanded 200 basis points to 21.2%.
Primo held cash, cash equivalents and restricted cash of $449.7 million as of March end.
Operating cash flow for the quarter totaled $38.8 million.
On May 1, 2025 Primo Brands announced that its Board of Directors declared a dividend of 10 cents per share, payable on June 17, 2025, in cash, to the holders of record of such common stock of the Company at the close of business on June 6, 2025.
Outlook Reaffirmed: For 2025, Primo sees net sales growth of 3% – 5%.The company expects adjusted EBITDA of $1.6 billion – $1.628 billion.
Primo expects adjusted free cash flow of $790 million – $810 million. 
Price Action: PRMB shares traded lower by 2.71% at $31.97 at last check on Thursday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">Under Armour Faces Tough Road Ahead, Says Analyst</a></li>
</ul>
Image: Shutterstock

PRMB

Primo Brands Cools As Beverage Company Misses Wall Street Estimates

Restaurant Brands International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45279852/restaurant-brands-international-inc-reports-first-quarter-2025-results" rel="noreferrer noopener">first-quarter revenue growth</a> of 21.3% year-on-year to $2.11 billion, missing the analyst consensus estimate of $2.13 billion.
Consolidated comparable sales increased 0.1%, and net restaurants grew 3.3% versus the prior year. Consolidated system-wide sales increased 2.8%.
Comparable sales for Tim Hortons&nbsp;fell&nbsp;0.1%, Burger King decreased&nbsp;1.3%, and Popeyes Louisiana Kitchen slumped&nbsp;4%. Revenue for Burger King rose 1.8%, and Popeyes Louisiana Kitchen increased 9%, while that of Tim Hortons fell 3.7% year over year.
Adjusted EPS of 75 cents <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the consensus</a> estimate of 78 cents, but grew compared to 73 cents last year.
General and administrative expenses increased 10.4%. The operating income for the quarter declined 20% to $435 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45272097/kellogg-has-margin-opportunity-but-challenges-keep-shares-grounded-says-analyst" rel="noreferrer noopener">Long-Term Decline In Cereal Market Poses Structural Challenges For Kellogg, Analyst Says</a>
Adjusted EBITDA for the quarter was $642 million, up from $627 million in the prior year.
Restaurant Brands held $899 million in cash and equivalents as of March-end. Net cash provided by operating activities for the quarter totaled $118 million.
Restaurant Brands' Board of Directors has declared a dividend of $0.62 per common share, payable on July&nbsp;8, 2025, to shareholders and unitholders of record at the close of business on June&nbsp;24, 2025.
"We are making solid progress executing the fundamentals of our business, despite a slower start to the year. We have clear growth plans across each of our brands and strong alignment with our franchisees," said CEO&nbsp;Josh Kobza.
"We're seeing encouraging momentum in Q2 and combined with responsible cost management, are on track to deliver stronger results through the balance of the year and achieve at least 8 percent organic adjusted operating income growth in 2025."
Outlook: Restaurant Brands&nbsp;sees FY25 capital expenditures of $400 million &#8211; $450 million.
For the long term, from 2024 to 2028, Restaurant Brands&nbsp;expects a comparable sales growth of 3% and an organic adjusted operating income growth of 8%.
Price Action: QSR shares traded lower by 0.29% at $67.70 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44907247" target="_blank" rel="noreferrer noopener">Restaurant Sector Q1 Volatilty From Weather, Inflation — Analyst Lowers Price Targets</a></li>
</ul>
Photo by Savvapanf Photo via Shutterstock

Guidance

Most Of Burger King Parent Restaurant Brands Growth Came From New Restaurants; It Plans Up To $450 Million In 2025 Capex

Keybanc analyst Noah Zatzkin maintains Acushnet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) with a Overweight and raises the price target from $70 to $75.

GOLF

Keybanc Maintains Overweight on Acushnet Holdings, Raises Price Target to $75

Curtiss-Wright shares are trading higher after the company reported better-than-expected Q1 results and raised its FY25 earnings and sales guidance.

Federal Reserve

President Trump Says BOE Cut, China Cut, Everyone Is Cutting But Powell; Powell Probably Not In Love With Me; Rate Cuts Would Be Like Jet Fuel

Press Releases

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Health Care

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Comments

Aura Biosciences

Noticias

Últimas noticias sobre Aura Biosciences (NASDAQ:AURA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL